
Overview
This review discusses the biomanufacturing of NK cell therapies, covering cell sources, expansion methods, and process control. It identifies G-Rex® as a commonly used culture system for clinical-scale NK cell production due to their gas-permeable membranes, facilitating efficient cell expansion.
What this paper found
Allogeneic natural killer (NK) cell therapy will need manufacturing processes that borrow from protein biologics production while treating the cells themselves as the final product. This review describes NK cell sources, including donor peripheral blood, cord blood, induced pluripotent stem cells and the NK-92 line, and the central role of engineered K562 feeder cells in expansion. Co-culture with K562/mbIL-21–4-1BBL feeder cells gave 10^4- to more than 10^6-fold expansion over 3–7 weeks. Current clinical-scale systems include bags, G-Rex® flasks and the CliniMACS Prodigy, whereas future scale may need 10–100 L stirred tanks, perfusion with cell retention, in-line sensing under process analytical technology, and quality by design frameworks. Processes would run from thawed banked cells through seed bioreactors to a production bioreactor, with periodic feeder cell additions.
Note: The authors note that feeder cell-free expansion systems have not yet been shown to sustain weeks of active growth.
However, large-scale expansion of NK cells is critically distinct from the production of recombinant proteins in that NK cells are the final product. — Pedram Motallebnejad, Anne Kantardjieff, Frank Cichocki, Samira M. Azarin, Wei-Shou Hu, Trends in Biotechnology
Study details
- Authors
- Pedram Motallebnejad, Anne Kantardjieff, Frank Cichocki, Samira M. Azarin, Wei-Shou Hu
- Institution
- Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, MN, USA · bluebird bio, Cambridge, MA, USA · Department of Medicine, University of Minnesota, Minneapolis, MN, USA
- Journal
- Trends in Biotechnology
- Year
- 2023
- Cell type(s)
- NK Cells
- Application area
- Hematologic malignancy
How G-Rex® was used
This is a review of manufacturing technology rather than an experimental study, and it names stationary G-Rex® flasks with gas-permeable membranes for enhanced oxygen transfer, alongside bag systems, as the culture systems commonly used to produce NK and T cells for clinical trials. It treats those G-Rex® flasks as the current baseline against which much larger mixing bioreactors, such as stirred tanks of 10 to 100 L, are proposed for allogeneic NK cell batches of 10^11 to 10^12 cells. No G-Rex® vessel size is named.
Explore related
Full citation
Motallebnejad P, Kantardjieff A, Cichocki F, Azarin SM, Hu WS. Process engineering of natural killer cell-based immunotherapy. Trends Biotechnol. 2023;41(10):1314-1326.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.